Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 17, Issue 10, Pages 1462-1470Publisher
ELSEVIER SCI LTD
DOI: 10.1111/j.1469-0691.2011.03610.x
Keywords
Immunology; vaccine; visceral leishmaniasis
Categories
Funding
- Medical Research Council [G1000230, G0400786] Funding Source: researchfish
- MRC [G1000230, G0400786] Funding Source: UKRI
Ask authors/readers for more resources
Human visceral leishmaniasis (HVL) is the most severe clinical form of a spectrum of neglected tropical diseases caused by protozoan parasites of the genus Leishmania. Caused mainly by L. donovani and L. infantum/chagasi, HVL accounts for more than 50 000 deaths every year. Drug therapy is available but costly, and resistance against several drug classes has evolved. Here, we review our current understanding of the immunology of HVL and approaches to and the status of vaccine development against this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available